Will Allscripts Healthcare (USA Stocks:MDRX) price continue to rise in August?
 | By Ellen Johnson | Macroaxis Story |
Allscripts Healthcare (NASDAQ: MDRX), a prominent player in the Health Care Technology sector, has been experiencing a steady upward trajectory in its stock price, with a Day Typical Price of $12.63 and a Posible Upside Price of $15.18. With a strong Accumulation Distribution of 183.97 and a Daily Balance Of Power of 0.0625, the stock is showing signs of a bullish trend. The company reported a Net Income of $133.9M for the fiscal year ending in December, despite a loss in Net Interest Income of $13.2M. The company's operating income stood at $186.8M, with an Income Before Tax of $161.8M. The firm also managed to reduce its shares short from 9.3M in the prior month to 9.2M, indicating a decrease in bearish sentiment. Analysts have a consensus "Buy" rating on the stock, with an Analyst Target Price Estimated Value of $19.687, and a Wall Street Target Price of $18.44. The Analyst Highest Estimated Target Price is $26, suggesting significant potential for growth. The company's PE Ratio stands at 14.0111, with a PEG Ratio of 2.4237, indicating that the stock is reasonably priced relative to its earnings growth. With a Price Book of 1.7099 and a Price Sales of 1.2955, the stock appears to be undervalued, providing an attractive entry point for investors. As we move into August, the technical indicators and analyst ratings suggest that Allscripts Healthcare's stock could continue its upward trajectory. However, investors should monitor the market conditions and company fundamentals closely to make informed investment decisions. While some millennials may be indifferent towards the healthcare technology sector, it's beneficial to analyze Allscripts Healthcare Solutions in terms of its current potential. As previously suggested, Allscripts Healthcare is starting to decline as investors become increasingly bearish due to heightened sector volatility. Many of the company's stock price fluctuations reflect the overall market trends. The presence of strong fundamental indicators for the company suggests a short-term price swing for Allscripts' investors. Allscripts Healthcare is set to announce its earnings today, with the next quarterly report expected on August 3, 2023.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
Allscripts Healthcare (NASDAQ: MDRX) has been demonstrating a steady upward trajectory, with a current price of $12.62, nearing its 52-week high of $19.77. The company's robust operating income of $186.8M and net income from continuing operations of $134M indicate strong financial health. Despite a high PEG ratio of 2.42, the company's PE ratio is at a reasonable 14.01, suggesting the stock may be undervalued. However, investors should be cautious of the relatively high shares short prior month at 9.3M, indicating potential market skepticism. The stock's beta of 0.9464 suggests it is less volatile than the market, making it a potentially safer investment in turbulent times.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Allscripts Healthcare. Your research has to be compared to or analyzed against Allscripts Healthcare's peers to derive any actionable benefits. When done correctly, Allscripts Healthcare's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Allscripts Healthcare.
Advanced assessment of Allscripts
The average rating for Allscripts Healthcare Solutions is 'Buy', as determined by nine analysts. Is this consensus based on technical analysis? Typically, technical analysis employs the use of price momentum, patterns, and trends derived from historical prices. The objective is to identify signals based on the market sentiment of Allscripts Healthcare investors, which is essentially their perception of the company's future value. Let's delve into a few elements of Allscripts' technical analysis.
Using predictive technical analysis, we can analyze different prices and returns patterns and diagnose historical swings to determine the real value of Allscripts Healthcare Solutions. In general, sophisticated investors focus on analyzing Allscripts Healthcare stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Allscripts Healthcare's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Allscripts Healthcare's intrinsic value. In addition to deriving basic predictive indicators for Allscripts Healthcare, many experienced traders also check how macroeconomic factors affect Allscripts Healthcare price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Allscripts Healthcare's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How does Allscripts Stands against Peers?
Analyzing Allscripts Healthcare competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Allscripts Healthcare across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out Allscripts Healthcare Competition DetailsA Deeper Perspective
Allscripts Healthcare has a beta of 1.3719. Let's try to break down what Allscripts's beta means in this case. Allscripts Healthcare returns are very sensitive to returns on the market. As the market goes up or down, Allscripts Healthcare is expected to follow. The beta indicator helps investors understand whether Allscripts Healthcare moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Allscripts deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. The entity reported the previous year's revenue of 1.5 B. Net Income was 133.9 M with profit before overhead, payroll, taxes, and interest of 738.26 M. Allscripts Healthcare Solutions (NASDAQ: MDRX), a key player in the Health Information Services industry, has been displaying promising technicals that suggest a bullish trend for August.The company's current valuation stands at $1.11B, while its market capitalization is $1.38B. With a 52-week high of $19.77, the stock's typical day price hovers around $12.63, indicating potential for growth. The company's robust financial health is evident in its current ratio of 3.23X, indicating its ability to meet short-term obligations. Allscripts' net assets amount to $2.43B, with retained earnings of $767.56M. The company's operating margin is at 0.0472%, with an operating income of $186.8M. Despite a negative net interest income of $13.2M, Allscripts has managed to keep its total debt to a manageable $434.5M. The company's shares are majorly owned by institutions, at 97.48%, which shows strong market confidence. However, with a short percent of 0.1316 and 9.16M shares shorted, investors should be cautious of potential short-term volatility. In conclusion, Allscripts' solid financials and promising technicals make it a stock to watch in August. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Allscripts Healthcare Solutions. Please refer to our Terms of Use for any information regarding our disclosure principles.